NCT07511426 2026-04-06
U96-CAR-T-Cells For R/R B-ALL
The First Affiliated Hospital of Soochow University
Phase 1 Recruiting
Clinical Trials
85 trialsNCT06208735 2026-04-03
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
British Columbia Cancer Agency
Phase 1 Recruiting
NCT07487428 2026-03-23
CLL-IMPACT
Technical University of Munich
Phase NA Recruiting
NCT07422337 2026-02-25
BOOSTER
Arkansas Children's Hospital Research Institute
Recruiting
NCT07337967 2026-01-13
Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative Neoplasms
Assiut University
Not yet recruiting
NCT02787369 2026-01-07
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT07166549 2025-12-24
BaseCAR-01
University Hospital, Basel, Switzerland
Phase 1 Not yet recruiting
NCT06345027 2025-12-16
CASEY
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT02650414 2025-12-12
CD22 Redirected Autologous T Cells for ALL
University of Pennsylvania
Phase 1 Active not recruiting
NCT03766763 2025-11-26
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A
French Innovative Leukemia Organisation
Phase 2 Active not recruiting
NCT03573700 2025-11-18
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT02050347 2025-11-14
CARPASCIO
Baylor College of Medicine
Phase 1 Active not recruiting
NCT05010564 2025-11-13
TRICAR-ALL
Baylor College of Medicine
Phase 1 Recruiting
NCT03050190 2025-09-08
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT03125577 2025-09-08
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT05779930 2025-08-15
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
Nationwide Children's Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT07113132 2025-08-08
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia
Assiut University
Not yet recruiting
NCT06812715 2025-08-06
PIPOZA
Peter MacCallum Cancer Centre, Australia
Phase 2 Recruiting
NCT03774654 2025-07-01
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
Baylor College of Medicine
Phase 1 Active not recruiting
NCT01683279 2025-06-17
A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT04515238 2025-06-10
CLL2-BZAG
German CLL Study Group
Phase 2 Active not recruiting
NCT04883749 2025-06-08
CLL-Frail
German CLL Study Group
Phase 2 Completed
NCT03804372 2025-02-27
CLL1818
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Terminated
NCT06834529 2025-02-19
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1/2 Recruiting
NCT06821880 2025-02-12
PRO-SID
Medical University Innsbruck
Recruiting
NCT06762431 2025-01-07
VTB-CLL002
Vitebsk Regional Clinical Cancer Centre
Phase 1/2 Enrolling by invitation
NCT04608318 2024-12-31
CLL17
German CLL Study Group
Phase 3 Active not recruiting
NCT03787264 2024-12-30
CLL2-BAAG
German CLL Study Group
Phase 2 Completed
NCT04605666 2024-08-20
CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies
Nanfang Hospital, Southern Medical University
Phase 2 Completed
NCT01597219 2024-05-03
UK-Haplo
University College, London
Phase 2 Completed
NCT06355739 2024-04-09
CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Recruiting
NCT03098355 2024-03-18
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
Zhujiang Hospital
Phase 1/2 Withdrawn
NCT04090268 2024-01-02
SportTherapy
University of Milano Bicocca
Phase NA Unknown
NCT05082519 2023-10-26
IDEAL2
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2 Recruiting
NCT05350826 2023-09-21
THEMIS
University Hospital, Toulouse
Phase NA Unknown
NCT05932173 2023-07-11
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2 Unknown
NCT05095155 2023-03-14
Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Kazakh Nationality
Asfendiyarov Kazakh National Medical University
Completed
NCT03899337 2023-01-09
STELLAR
University of Birmingham
Phase 2 Recruiting
NCT05570188 2022-11-30
Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies
Kunming Hope of Health Hospital
Phase 1/2 Withdrawn
NCT03852407 2022-10-12
HLA
University of Liege
Phase 2 Recruiting
NCT05099068 2022-07-05
PLANET
Centre Leon Berard
Phase NA Unknown
NCT03564470 2022-07-01
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT04260945 2022-03-08
CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients
Hebei Yanda Ludaopei Hospital
Phase 1 Completed
NCT03068416 2021-10-20
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy
Uppsala University
Phase 2 Completed
NCT02933320 2021-07-08
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
Cancer Research UK
Phase 1/2 Completed
NCT03605589 2021-04-01
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
Children's Hospital Medical Center, Cincinnati
Phase 1 Withdrawn
NCT04747093 2021-02-10
Induced-T Cell Like NK Cells for B Cell Malignancies
Nanfang Hospital, Southern Medical University
Phase 1/2 Unknown
NCT03294980 2021-01-28
OFICE
University Hospital, Brest
Unknown
NCT04516551 2020-11-17
Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT
Xinqiao Hospital of Chongqing
Phase 1 Unknown
NCT03302403 2020-10-08
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
First Affiliated Hospital of Wenzhou Medical University
Phase NA Unknown